BioSig Technologies Appoints New Chief Financial Officer

BioSig Technologies Inc., a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, has appointed Steven Chaussy as chief financial officer (CFO).
 
Chaussy brings over 30 years of financial and operating experience to the company. Prior to joining BioSig Technologies, Chaussy has been the sole proprietor of Anna & Co. Inc., a consulting company that offers financial and accounting services to small publicly traded companies. Chaussy has an extensive entrepreneurial growth and development background learned from working for Penske Truck Leasing Co. L.P., a subsidiary of Penske Corporation, where his improvements of management and reporting tools have allowed the company to double in size.

“Steve has been supporting BioSig from the very beginning of our journey. As we step up our efforts towards commercialization, we needed a highly experienced, full-time CFO with the strong expertise in supporting emerging growth companies and successfully managing rapidly developing environments,” stated Kenneth Londoner, chairman and CEO of BioSig Technologies.  “Steve’s ability to navigate complex markets is a definite value-add in both our pre-commercial activities and future growth of our organization.”
 
During his career, Chaussy also served as CFO to a number of private and public companies. The systems introduced by Chaussy have been key drivers of profitability and development of international business lines. Chaussy is a certified public accountant and received his degree in accounting from Virginia Polytechnic Institute and State University.
 
In his role as CFO, Chaussy will be responsible for ensuring the financial organization required to support the company’s growth strategy while establishing a strong foundation for long-term progress.
 
“I am both honored and excited to be joining the BioSig team at such a key point in their trajectory,” said Chaussy. “I am impressed with the company current assets, management team and near-term commercialization prospects. I look forward to contributing to the future success of the company.”
 
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace. Led by a management team and a veteran, independent Board of Directors, Los Angeles, Calif.-based BioSig Technologies is preparing to commercialize its PURE EP System.  The technology has been developed to address an unmet need in a large and growing market.

The company’s first product, PURE EP System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, atrial fibrillation and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward U.S. Food and Drug Administration 510(k) clearance for the PURE EP System.